Five presentations demonstrate Galapagos' commitment to inflammation and the ulcerative colitis (UC) communityNew analyses will be presented from the SELECTION data set on prediction of response and remission
Investegate announcements from Galapagos NV, Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress
Dracen Announces DRP-104 (sirpiglenastat) Presentation at ASCO 2021 Virtual Annual Meeting
Share Article
Trial in progress poster: Phase 1 & Phase 2a, first-in-human study (FIH) of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors NEW YORK (PRWEB) June 03, 2021 Dracen Pharmaceuticals Inc., announced today that a poster presentation updating the ongoing Phase 1/2a, FIH study of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors will be presented during the trial in progress session at the ASCO virtual meeting June 4th- 8th, 2021.
The presentation details are as follows: Title: Phase 1 & Phase 2a, first-in-human study (FIH) of DRP-104, a broad glutamine antagonist, in adult patients with
MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights
-Topline TIDAL Study Data Evaluating Zandelisib in Relapsed or Refractory Follicular Lymphoma on Track to be Reported in the Fourth Quarter-
- MEI Maintains Strong Financial Position with ~$164 Million in Cash-
News provided by
Share this article
Share this article
SAN DIEGO, May 6, 2021 /PRNewswire/ MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2021 and highlighted recent corporate progress. The first several months of 2021 have been very eventful for MEI, highlighted by the completion of enrollment in the follicular lymphoma efficacy population arm of the zandelisib TIDAL study. In addition, we recently reported preclinical data at AACR 2021, demonstrating the ability of voruciclib to downregulate MYC and synergize with KRAS inhibitors in KRAS mutant cancers, said Da
MEI Pharma Reports Third Quarter Fiscal 2021 Results and Operational Highlights
-Topline TIDAL Study Data Evaluating Zandelisib in Relapsed or Refractory Follicular Lymphoma on Track to be Reported in the Fourth Quarter-
- MEI Maintains Strong Financial Position with ~$164 Million in Cash-
News provided by
Share this article
Share this article
SAN DIEGO, May 6, 2021 /PRNewswire/ MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended March 31, 2021 and highlighted recent corporate progress. The first several months of 2021 have been very eventful for MEI, highlighted by the completion of enrollment in the follicular lymphoma efficacy population arm of the zandelisib TIDAL study. In addition, we recently reported preclinical data at AACR 2021, demonstrating the ability of voruciclib to downregulate MYC and synergize with KRAS inhibitors in KRAS mutant cancers, said Da